ArticleThe oncologist2020

FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Donna Przepiorka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.